Early next year, Spark Therapeutics Inc.’s gene therapy Luxturna could become the first such treatment for an inherited condition to win approval in the U.S., bringing with it new hope for patients with a rare form of childhood blindness.
At the same time, the one-time treatment will likely command a premium price, putting the promise of gene therapy in stark relief to questions of affordability and access.
Spark has yet to determine a price for its treatment. Yet recent comments from the biotech’s CEO suggest Luxturna’s cost could approach the $1 million mark, which would make the gene therapy one of the most expensive medicines on the market.
You must be logged in to post a comment.